Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SH491 (Compound 33) serves as an antiosteoporosis agent, effectively inhibiting RANKL-induced osteoclast differentiation in bone-marrow-derived monocytes (BMMs) with an IC50 of 11.8 nM. Additionally, SH491 suppresses the expression of genes and proteins related to osteoclastogenesis, specifically TRAP, CTSK, MMP-9, and ATPase v0d2 [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | SH491 (Compound 33) serves as an antiosteoporosis agent, effectively inhibiting RANKL-induced osteoclast differentiation in bone-marrow-derived monocytes (BMMs) with an IC50 of 11.8 nM. Additionally, SH491 suppresses the expression of genes and proteins related to osteoclastogenesis, specifically TRAP, CTSK, MMP-9, and ATPase v0d2 [1]. |
Molecular Weight | N/A |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.